- Effect of pomalidomide treatment in highly pretreated and poor-risk multiple myeloma patient2014 | Publication without faculty affiliation
- Impact of immunomodulatory drugs in treatment of primary myelofibrosis2015 | Faculty of Medicine in Hradec Králové
- Diagnosis and treatment of multiple myeloma2014 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- The role of elotuzumab in the treatment of multiple myeloma2021 | First Faculty of Medicine
- Real-world evidence of efficacy and safety of pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: Czech registry data2022 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové, Central Library of Charles University, Faculty of Medicine in Pilsen
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study2019 | First Faculty of Medicine
- Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study2022 | First Faculty of Medicine
- Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis2021 | Faculty of Medicine in Hradec Králové
- Elotuzumab in the treatment of multiple myeloma2020 | First Faculty of Medicine
- Antibody interference and response kinetics of isatuximab plus pomalidomide and dexamethasone in multiple myeloma2021 | First Faculty of Medicine
- Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study2022 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study2021 | First Faculty of Medicine
- Mnohočetný myelom2016 | First Faculty of Medicine
- Komentář ke studii2020 | First Faculty of Medicine
- Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma2016 | Faculty of Medicine in Hradec Králové
- Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma2018 | First Faculty of Medicine
- Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR2018 | First Faculty of Medicine
- Isatuximab for the treatment of relapsed/refractory multiple myeloma2020 | First Faculty of Medicine
- Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies2023 | First Faculty of Medicine
- Combination Therapy Using Invariant Natural Killer T Cells and Immunomodulatory Drugs in Multiple MyelomaPublication without faculty affiliation
- Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA2022 | First Faculty of Medicine
- AL amyloidosis: advances in diagnostics and treatment2019 | First Faculty of Medicine
- Evaluation of isatuximab in patients with soft-tissue plasmacytomas: An analysis from ICARIA-MM and IKEMA2022 | First Faculty of Medicine
- Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients2018 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial2021 | First Faculty of Medicine
- Ixazomib, Lenalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma in Routine Clinical Practice: Extended Follow-Up Analysis and the Results of Subsequent Therapy2022 | First Faculty of Medicine, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové